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One of the most enduring models of human disease now
celebrates the seventieth anniversary of its publication in
 
The Journal of Experimental Medicine
 
. Thomas Rivers, work-
ing at the Hospital of the Rockefeller Institute for Medical
Research, along with his colleagues D.H. Sprunt and G.P.
 
Berry, submitted the article entitled, “Observations on
Attempts to Produce Disseminated Encephalomyelitis in
Monkeys,” on Feb. 21, 1933 (1). Rivers established this
model to try to understand what caused neurological reac-
tions to certain viral infections like smallpox and in some
circumstances to vaccinations like rabies: the very first sen-
tence of this landmark paper reads, “During convalescence
from certain diseases notably smallpox, vaccinia and mea-
sles, and during or following vaccination against rabies, an
occasional patient develops symptoms and signs referable to
the central nervous system.” One of the most devastating
complications of vaccination and viral infection is acute op-
 
tic neuritis (2). In the current issue, Bettelli and colleagues
have been able to establish a model of acute optic neuritis,
without accompanying inflammation elsewhere in the cen-
tral nervous system (3).
 
The Optic Neuritis Model of EAE.
 
There are multiple
forms of autoimmune demyelination. About 10 to 30% of
patients with multiple sclerosis have a clinical presentation
that starts with an attack of optic neuritis, sometimes ac-
companied by other findings (4). Rates vary due to ascer-
tainment biases: ophthalmologists may report higher rates
of optic neuritis than neurologists, for the obvious reason
that patients and referring physicians turn to ophthalmolo-
gists first. In some cases there is optic neuritis with no obvi-
ous evidence of inflammation outside the visual system.
About a third of the time optic neuritis is a harbinger of
further attacks elsewhere in the central nervous system
leading to a diagnosis of multiple sclerosis. To date there
have been no reproducible experimental systems where we
have a model of either pure optic neuritis, optic neuritis
plus inflammation elsewhere in the central nervous system,
or inflammation elsewhere in the central nervous system
without optic neuritis. In this issue, Bettelli and colleagues
have discovered such models in a transgenic mouse with
TCRs recognizing the major encephalitogenic epitope of
myelin oligodendroglial glycoprotein (MOG) in H-2b
mice (3). 30% of these MOG-specific TCR transgenic
mice spontaneously develop pure optic neuritis. The optic
nerve interestingly contains more MOG, than elsewhere in
the central nervous system. If these transgenic mice are im-
munized with MOG35–55 plus pertussis toxin, then they
develop optic neuritis plus inflammation elsewhere in the
central nervous system. The role of an exogenous toxin in
this model of genetically determined autoimmunity, pro-
vides a brilliant opportunity to assess the interplay of genes
and environment in autoimmunity.
 
The Topology of Immunology: Autoimmunity and Allergy
Are Joined In EAE.
 
Since its first description by Rivers
the model has served as a starting point for our understand-
ing of autoimmunity (Table I and Fig. 1). The “
 
A
 
” in the
acronym EAE, mutated from experimental 
 
allergic
 
 to exper-
imental 
 
autoimmune
 
 encephalomyelitis, sometime in the
70’s (Table II). Now the boundaries between these two
seemingly opposite poles of immunity are coming together
as if the contour of immunity was more spherical than flat.
We are learning from studies on the EAE model that com-
ponents of the allergic response are critical in the modula-
tion of Th1 autoimmunity (5, 6).
The boundary between allergy and autoimmunity can
be blurred: it is possible to induce “horror autotoxicus”
with anaphylaxis against certain self-antigens, exemplified
by myelin peptides (5). Further, Th2 T cells are capable of
inducing EAE with features that include eosinophilic in-
flammation, sometimes also present in MS (7). Further-
more mast cells are present in MS lesions, and PAF-R and
tryptase are elevated in the spinal fluid of MS patients (6,
8). Analysis of mRNA from multiple sclerosis (MS) le-
sions revealed increased amounts of transcripts for several
 
genes encoding molecules traditionally associated with
allergic responses, including prostaglandin D synthase
(PGDS), histamine receptor type 1 (H1R), platelet acti-
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vating factor receptor (PAFR), Ig Fc
 
 
 
 receptor 1 (Fc
 
 
 
RI),
and tryptase (8, 9).
In EAE, mediated by Th1 T cells, histamine receptor 1
and 2 (H2R) are present on inflammatory cells in brain le-
sions. Histamine receptor genes confer susceptibility to
EAE (10). Th1 cells reactive to proteolipid protein (PLP)
expressed more H1R and less H2R than Th2 cells. An
H1R antagonist, blocked EAE and a PAFR antagonist re-
duced the severity of EAE. EAE severity was also decreased
in mice with disruption of the genes encoding Ig Fc
 
 
 
RIII
and both Fc
 
 
 
RIII and Fc
 
 
 
RI. PGDS and tryptase tran-
scripts were elevated in EAE brain (6). EAE is attenuated in
mast cell–deficient mice (11). Taken together, these data
reveal extensive involvement of elements of the immune
response associated with allergy in autoimmune demyelina-
tion. The role of mast cells in autoimmune disease also
presents a challenge to our understanding of the patho-
physiology of these disorders, previously thought to be dia-
metrically opposite to allergy. The pathogenesis of demy-
elination must now be viewed as encompassing elements of
both Th1 responses and “allergic” responses: allergy and
autoimmunity are not antipodal.
 
Recent Revelations from EAE: Surprising Roles for Starvation,
Stress, and Cholesterol Metabolism.
 
Leptin, a molecule that
is critical in the regulation of energy balance and body
weight, is a strong regulator of Th1 autoimmunity, as dem-
onstrated by its potent influence on EAE (12, 13, 14). This
is one of many examples of redundancy and overlapping
roles of molecules within neuroendocrine systems and the
immune system: for example, it had been shown that corti-
cotropin releasing factor (CRF), a master regulator of hy-
pothalamic and pituitary function, has an autonomous ef-
fect on the immune system. CRF can down-regulate Th1
 
autoimmunity, and block EAE (15). The neuroendocrine
system can have potent effects on the immune system: basic
behaviors like fasting have potent influences on the induc-
tion of Th1 autoimmunity. A short fast can circumvent an
attack of autoimmune paralysis in EAE (13). Thus, while
“feeding a cold” may have salutary effects on combating a
viral infection, starving an autoimmune disease, exempli-
fied by EAE, may protect against immune damage.
While “simple” acts like fasting influence immunity,
complicated states like pregnancy modulate autoimmune
diseases, as strongly as any known drug (16). Gender itself
has an impact on autoimmunity, females being far more
susceptible than males to diseases like systemic lupus
erythematosus, rheumatoid arthritis, autoimmune thyroidi-
tis, and multiple sclerosis (4). In EAE female mice are far
more susceptible to disease than males. Pregnancy amaz-
ingly ameliorates EAE (4), while genes associated with
pregnancy are found in MS lesions (8). Interestingly, fe-
males produce more leptin than males (13). This may in
part account for the increased susceptibility of females to
many organ specific autoimmune diseases, like MS and
rheumatoid arthritis.
In EAE we witness the remarkable choreography of
molecules related to body weight and energy metabolism
and the parallel roles of these same molecules in the finely
tuned immune response. Studies in EAE have opened an
interesting frontier in our understanding of how the brain
influences the immune system. Another molecule HMG-
CoA reductase is also modulated in MS brain. Recent evi-
dence indicated that statins, inhibitors of HMG-CoA re-
ductase, and the fundamental class of drugs used to lower
cholesterol, may act to block the inducible expression of
the class II major histocompatibility molecules. Earlier
studies by McDevitt and colleagues had shown that block-
ade of MHC class II was effective in reversing EAE (17).
Statins have now been shown remarkably to block ongoing
paralysis and relapses in EAE, and to promote Th2 immu-
nity. Increased phosphorylation of the transcription factor
for Th2 cytokines, Stat 6, as well as decreased expression of
MHC class II molecules in MS brain are consequences of
oral administration of statins. Preliminary trials are under-
way in patients with MS, based on these preclinical results
in mice with EAE (18).
 
EAE Provides a System To Test for New Therapies of Au-
toimmunity and Perhaps Vaccine Complications.
 
EAE has
served as a useful tool for the preclinical testing of new ap-
proaches to Th1 autoimmunity. Those therapies which ac-
tually reverse established EAE have shown some promise in
the clinic. Perhaps most noteworthy has been the develop-
ment of the random copolymer of tyrosine, glutamate, ala-
nine, and lysine, with the relative concentrations of the
amino acids formulated to resemble that of myelin basic
protein. First invented by Teitelbaum, Arnon, and Sela at
the Weizmann Institute the drug was shown to block EAE
(19). The drug advanced through clinical trials over a pe-
riod approaching 20 years, and is now an approved drug for
multiple sclerosis, because of its ability to diminish the rate
 
Table I.
 
Similarities between Experimental Encephalomyelitis and 
Multiple Sclerosis
 
EAE MS
1. Genetic susceptibility Strong association with
MHC class II
 
  
 
2. Environmental triggers Strong association with
prior infection
 
  
 
3. White matter pathology Predominance of Th1
T cells in lesions
 
  
 
4. Grey matter pathology Axonal degeneration
 
  
 
5. Clinical presentation Optic neuritis common
in initial attack
 
  
 
6. Clinical forms Relapsing/remitting,
progressive forms
 
  
 
7. Clinical progression Osteopontin important
in progression
 
  T
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of relapse. More recently 
 
 
 
4 integrin antibodies, shown to
block the migration of T cells into the brain in EAE (20),
has shown promise in controlled trials for multiple sclerosis
and for inflammatory bowel disease (21). Antegren reduces
the frequency of relapses and reduces activity on magnetic
resonance brain scans (21).
The world is now confronting the specter of bioterror-
ism. Acute disseminated encephalomyelitis (ADE) after
smallpox immunization (2) is one reason that vaccination
programs are considered with fear and trepidation. Given
the number of countermeasures to reverse EAE, perhaps
we should be investing more resources on measures to pre-
dict who might be susceptible to such complications, and
how to deal with such complications when they occur.
Large scale proteomic approaches to monitoring autoim-
mune responses to central nervous system antigens (22), are
in development and may offer at least a practical system for
assessing who might become at risk for ADE.
The EAE model might be completely renamed NSRV,
neurological syndrome referable to vaccination. In this
context, the latest version of this EAE, acute optic neuritis
described by Bettelli and colleagues (3) provides a test sys-
tem for investigating one of the most common clinical pre-
sentations of an adverse reaction to routine vaccination.
The latest revelation gained from studying EAE, a model
for optic neuritis, demonstrates the utility of EAE over a
period of time that has spanned the Great Depression,
World War II, the discovery of the double helical nature of
DNA, and now the unfortunate and chilling specter of bio-
terrorism. EAE may be there to help.
 
EAE Has Attracted Many of the Best and the Brightest.
 
My colleague Howard Weiner, who himself has contrib-
uted to our understanding of mechanisms of tolerance in
EAE, estimated that nearly 5,000 papers have been written
using the EAE model since its inception (23). Sometimes
one is inclined to think that the best science and the best
scientists work on 
 
C. elegans
 
, zebrafish, or Drosophila. The
EAE model has attracted some of the most influential im-
munologists of the last seventy years: two Nobel Prize win-
ners in Medicine and Physiology, including Susumu Tone-
Figure 1. In EAE T lymphocytes gain access to the CNS via their  4 integrins, recognizing VCAM on the blood vessel wall (references 4, 20, and 21).
The T cells diapedese through the endothelium, using matrix metalloproteases to cleave collagen IV in the extracellular matrix (reference 4). Once
within the CNS they release inflammatory cytokines. The B cell and the mast cell also contribute to pathology (reference 4). Complement plus antibody
leads to activation of membrane attack complexes which attack the myelin sheath (reference 4). EAE can be blocked by an  4 integrin antibody (refer-
ence 20). Antegren which recognizes human  4 integrin has shown promise in phase II trials in MS (reference 21). Statins (reference 18) and altered pep-
tide ligands (references 51 and 52) can interfere with the recognition of myelin fragments by inducible MHC class II in the CNS (reference 4). Antihista-
mines and platelet activating receptor antagonists can block mast cell activity in EAE (reference 6).T
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gawa (7) and Peter Doherty (24) have worked on EAE,
while Stan Prusiner was involved in the cloning of myelin
basic protein (25). Tonegawa showed that Th2 T cells
could induce EAE in some instances (7), while Doherty
worked on the role of iron chelators in regulating EAE
(24). Elvin Kabat first used the adjuvant invented by Jules
Freund to induce EAE with a single injection in monkeys
(26). Byron Waksman established the roles of inflammatory
cytokines in autoimmunity, and the role of the thymus us-
ing this model (27). Phil Paterson demonstrated that cells
could transfer the disease, not antibodies (28). Jonas Salk,
renowned for his work on poliomyelitis, engaged in re-
search on myelin basic protein in EAE with Ed Eylar at the
Salk Institute in its earliest days (29). Irun Cohen and Hart-
mut Wekerle, along with their student Avi Ben-Nun, dem-
onstrated that it was possible to immunize against the re-
ceptor on T cells and thereby modulate autoimmunity
 
(30). Michael Sela and Ruth Arnon pioneered synthetic
approaches to the treatment of EAE, culminating in one of
the two types of drugs now approved for immunotherapy
of MS, Copaxone (19). Hugh McDevitt used the model to
demonstrate that peptide based therapeutics aimed at the
MHC could serve as an effective therapeutic approach (31,
32). Jack Strominger has refined the use of peptides that in-
teract with MHC molecules as a means for improving ther-
apies for autoimmunity (33). Len and Lee Herzenberg
demonstrated at about the same time as Don Mason and
Steve Brostoff (34, 35), that CD4 T cells were critical in
inducing autoimmune demyelination. The Herzenbergs
and Vernon Oi, employed the then emerging technologies
of monoclonal antibodies to target these T cells, including
the creation of chimeric monoclonal antibodies, selecting
for rare isotype switch variants using flow cytometry, or
engineering the chimeric molecules (35, 36). Leroy Hood,
who was the first to clone myelin basic protein along with
Stan Prusiner (25), established a TCR transgenic model of
autoimmunity using EAE, and showed that factors in the
environment were a key trigger for induction of clinical
disease (37).
Charles Janeway studied the role of adhesion molecules
in lymphocyte migration to the CNS (20, 38). Marc Feld-
mann has extended to the realm of EAE and MS, his ele-
gant work on blocking cytokines, work that has lead to a
revolution in therapy for rheumatoid arthritis (39). Eli Ser-
carz reported the phenomenon of epitope spreading for the
first time in EAE (40). Ethan Shevach studied the role of
CpG motifs in DNA in the modulation of EAE (41). The
CpG motifs contained in the mycobacteria that comprise
Freund’s adjuvant were probably the key in Kabat’s early
experiment (26). Harvey Cantor used the EAE model to
describe the role of ETA-1 in autoimmunity (9, 42).
Stephen Miller has applied his earlier work on tolerance in-
duction with covalently coupled antigen done with Henry
Claman to advance the studies to EAE, where he is induc-
ing tolerance on a broad front (43), while Halina Offner,
Art Vandenbark, and Jingwu Zhang have continued their
efforts to target rogue T cells with sophisticated vaccination
techniques (44, 45). Richard Flavell, who has used the
EAE model in many of his clever genetically engineered
mice, has created a T cell receptor modified lymphocyte
that triggers a Th2 response and modulates EAE, in his lat-
est creative effort (46). Howard Weiner and Caroline
Whitacre have pioneered approaches to harness mucosal
immunity and guide it toward a platform to induce tolerance
(23). The global nature of work on EAE is well known and
includes Yamamura’s work on the role of NK cells in EAE
(47), and the work of Claude Bernard, Ann Cross, Claude
Genain, and Steve Hauser on the role of antibodies to
MOG in demyelinating disease (48, 49). Cedric Raine has
discovered that there is injury to the underlying axon, me-
diated in part by glutamate, in the degenerative phase of
EAE (50, 51). Tak Mak, Hans Acha-Orbea, and Joan
Goverman have made important observations on the role
of CD8
 
 
 
 T cells in EAE (52, 53). Industry has made
important advances with this model, particularly Robert
 
Table II.
 
Time Line of EAE: Some Highlights of the
First 70 Years
 
The Allergic Encephalomyelitis Era
1. Establishment of the Model by Rivers 1933
2. Use of Freund’s Adjuvant by Kabat for Ease of Induction 
1947
3. Transfer of EAE with Lymph Node Cells by Paterson 1960
4. The Role of the Thymus in EAE by Waksman 1962
5. Immunomodulation with Peptide Polymers by Sela and
Arnon 1971
The Autoimmune Encephalomyelitis Era
6. Induction of EAE with T Cell Lines by Ben-Nun, Wekerle, 
Cohen 1981
7. Definition of an Encephalitogenic Epitope by Zamvil,
Rothbard, Steinman 1986
8. Modulation of EAE with Peptides by McDevitt, Steinman, 
Wraith 1989
9. Creation of T Cell Receptor Transgenic by Hood and 
Goverman 1991
10. Description of Epitope Spreading by Sercarz and Lehmann 
1992
11. Role of Adhesion Molecules in EAE by Yednock, Karin,
Steinman 1992
The Allergic/Autoimmune Encephalomyelitis Era
12. Axonal Degeneration and Glutamate Toxicity by Raine 
2001
13. Horror Autoxicus and Anti-histamines in EAE by Pedotti
and Teuscher 2001
14. Interplay of Endocrine Mediators in EAE by Matarese 
2003T
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Coffman and Jonathon Sedgwick at DNAX, who have ex-
tended the map of the Th1/Th2 paradigm on to the land-
scape of EAE (54). Scores of young investigators working
with these leaders in the field of immunology and working
independently established their research careers pursuing
studies on this durable model.
 
 “Many Rivers to Cross but Just Where to Begin.”
 
Per-
haps drawing on Thomas River’s name, we can think of
EAE in the context of the reggae ballad, “Many Rivers to
Cross” by Jimmy Cliff. What started out as a rigorous ex-
perimental attempt to reproduce one of the dreaded com-
plications of infection and vaccination, has now enriched
our understanding of this phenomenon, and has lead to the
development of new therapies for the major autoimmune
disease of the brain and spinal cord. In this world now fac-
ing the threat of bioterrorism it is worth remembering that
Rivers, Sprunt, and Berry made a very salient observation
predicting a strategy that could defuse the risk of horren-
dous neurological complications of vaccination: “We did
find, however, that the brain of a monkey vaccinated on
the skin rapidly becomes refractory to the active agent
placed in the cisterna magna and the parietal lobe.” This
deviation of an autoimmune response, via immunization
with a similar, or slightly altered antigen, via another route
is worthy of attention not only as a countermeasure for dis-
seminated encephalomyelitis, but as a treatment for MS it-
self (55, 56). The EAE model is robust at age 70, and it
would not be surprising to see that it is still serving as a
model system for understanding autoimmunity when it
reaches its 100th birthday in 2033.
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